Zacks Investment Research upgraded shares of Fibrocell Science Inc (NASDAQ:FCSC) from a hold rating to a buy rating in a research report report published on Wednesday morning. Zacks Investment Research currently has $4.25 price target on the stock.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Several other research firms have also recently weighed in on FCSC. ValuEngine upgraded Fibrocell Science from a strong sell rating to a sell rating in a report on Thursday, June 15th. HC Wainwright restated a buy rating and set a $5.70 price target on shares of Fibrocell Science in a report on Friday, June 9th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $3.36.
Fibrocell Science (NASDAQ:FCSC) opened at 3.83 on Wednesday. The company’s market cap is $56.28 million. The stock has a 50 day moving average of $2.75 and a 200 day moving average of $1.65. Fibrocell Science has a 52 week low of $1.57 and a 52 week high of $4.64.
Fibrocell Science (NASDAQ:FCSC) last issued its earnings results on Wednesday, May 10th. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.29. Fibrocell Science had a negative return on equity of 236.55% and a negative net margin of 4,307.60%. Equities research analysts predict that Fibrocell Science will post ($1.39) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://transcriptdaily.com/2017/07/18/fibrocell-science-inc-nasdaqfcsc-stock-rating-upgraded-by-zacks-investment-research.html.
An institutional investor recently raised its position in Fibrocell Science stock. Creative Planning boosted its stake in Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 61,090 shares of the company’s stock after buying an additional 48,755 shares during the period. Creative Planning owned about 0.42% of Fibrocell Science worth $245,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 54.97% of the company’s stock.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.